ZA200701044B - Compositions for delivering peptide YY and PYY agonists - Google Patents

Compositions for delivering peptide YY and PYY agonists

Info

Publication number
ZA200701044B
ZA200701044B ZA200701044A ZA200701044A ZA200701044B ZA 200701044 B ZA200701044 B ZA 200701044B ZA 200701044 A ZA200701044 A ZA 200701044A ZA 200701044 A ZA200701044 A ZA 200701044A ZA 200701044 B ZA200701044 B ZA 200701044B
Authority
ZA
South Africa
Prior art keywords
compositions
pyy agonists
delivering peptide
peptide
delivering
Prior art date
Application number
ZA200701044A
Other languages
English (en)
Inventor
Dinh Steven
Wang Huaizhen
Gomez-Orellana Maria Isabel
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of ZA200701044B publication Critical patent/ZA200701044B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
ZA200701044A 2004-07-12 2007-02-05 Compositions for delivering peptide YY and PYY agonists ZA200701044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58775104P 2004-07-12 2004-07-12

Publications (1)

Publication Number Publication Date
ZA200701044B true ZA200701044B (en) 2008-12-31

Family

ID=35839770

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701044A ZA200701044B (en) 2004-07-12 2007-02-05 Compositions for delivering peptide YY and PYY agonists

Country Status (12)

Country Link
US (2) US9399054B2 (es)
EP (1) EP1791553B1 (es)
JP (1) JP5749879B2 (es)
CN (2) CN101443028A (es)
AU (1) AU2005271878B2 (es)
BR (1) BRPI0513101A (es)
CA (1) CA2573512C (es)
HK (1) HK1107524A1 (es)
MX (1) MX2007000510A (es)
NZ (1) NZ552558A (es)
WO (1) WO2006017251A2 (es)
ZA (1) ZA200701044B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492505B2 (en) * 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
WO2011017335A1 (en) 2009-08-03 2011-02-10 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
KR101925620B1 (ko) 2010-12-16 2018-12-05 노보 노르디스크 에이/에스 Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CA2993215C (en) * 2015-07-02 2023-10-31 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
CN112055592A (zh) * 2018-01-09 2020-12-08 吉拉毒蜥治疗公司 用于治疗代谢疾病的组合物和方法
CA3087733A1 (en) * 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN108947862B (zh) * 2018-06-25 2020-10-16 上海龙灯环保科技有限公司 季戊四醇四((n,n-二(2-氨基乙基))-3-氨基丙酸酯)及其制备方法和应用
CA3126358A1 (en) * 2019-01-14 2020-07-23 Children's Hospital Medical Center Compositions and methods for treatment of a malabsorptive disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
ES2297909T3 (es) 1997-02-07 2008-05-01 Emisphere Technologies, Inc. Compuestos y composiciones para el suministro de agentes activos.
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
BRPI0015567B8 (pt) * 1999-11-05 2021-05-25 Emisphere Tech Inc composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
ATE450269T1 (de) * 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
BR0207871A (pt) * 2001-03-01 2004-06-22 Emisphere Tech Inc Composição para liberar bisfosfonato para um alvo
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004056314A2 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
MXPA05012278A (es) 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.

Also Published As

Publication number Publication date
US20110183898A1 (en) 2011-07-28
EP1791553A4 (en) 2012-09-05
WO2006017251A2 (en) 2006-02-16
AU2005271878B2 (en) 2010-02-18
EP1791553A2 (en) 2007-06-06
NZ552558A (en) 2009-11-27
CN105708787A (zh) 2016-06-29
US9399054B2 (en) 2016-07-26
JP2008505973A (ja) 2008-02-28
HK1107524A1 (en) 2008-04-11
JP5749879B2 (ja) 2015-07-15
BRPI0513101A (pt) 2008-04-29
US20160296599A1 (en) 2016-10-13
EP1791553B1 (en) 2013-10-23
CA2573512C (en) 2014-09-23
CN101443028A (zh) 2009-05-27
AU2005271878A1 (en) 2006-02-16
WO2006017251A3 (en) 2008-11-13
MX2007000510A (es) 2007-03-29
CA2573512A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
HK1107524A1 (en) Compositions for delivering peptide yy and pyy agonists
ZA200508848B (en) Compositions for delivering peptide yy and pyy agonists
IL184324A0 (en) Pyy agonists and uses thereof
EP1687017A4 (en) METHODS AND COMPOSITIONS FOR DISTRIBUTING POLYNUCLEOTIDES
EP1971355A4 (en) METHOD AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES WITH IMPROVED PHARMACOLOGICAL PROPERTIES
HK1112427A1 (en) Drug delivery compositions and related methods
IL217713A0 (en) Compounds and compositions for delivering active agents
ZA200706030B (en) GLP-1 agonists, compositions, methods and uses
PL1786272T3 (pl) Kompozycje rozgrzewające i układy do ich dostarczania
IL227910A0 (en) Flagellin-related polypeptides and uses thereof
IL173742A0 (en) Compositions for delivering 5-ht agonists across the oral mucosa
IL180350A0 (en) Compositions for delivering highly water soluble drugs
EP1773369A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PEPTIDE TREATMENT
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL179380A0 (en) Compositions comprising nicotinic and opioid agonists
IL184266A (en) Benzazole analogues, preparations containing them and their use as inhibitors of protein kinase
AU2003241313A8 (en) Compositions and methods for stem cell delivery
IL186337A0 (en) Stannsoporfin compositions and administration
HK1109335A1 (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use
EP1761244A4 (en) ISOCYANATE COMPOSITIONS AND USE THEREOF
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION
GB0406014D0 (en) Pharmaceutical composition and use
GB0413139D0 (en) Composition and delivery system
ZA200705348B (en) PYY agonists and uses thereof
GB0408398D0 (en) Leptin receptor agonists (3)